EUCTR2005-005449-20-IT进行中（未招募）1 期
Double blind, randomized, placebo-controlled, parallel-group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for Intermittent Allergic Rhinitis IAR . - ND
SCHERING-PLOUGH0 个研究点目标入组 547 人开始时间: 2006年12月6日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 547
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects 12 years of age or older, of either sex with at least a 2 year history consistent with allergic rhinitis who meet the criteria for IAR defined as symptoms of allergic rhinitis present less than four days per week or for less then four consecutive weeks per year .
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects with a history of anaphylaxis and/or severe local reactions to skin test with allergens or with intolerable symptoms that would make partecipating in the study unbearable. Subjects who have had an upper respiratory tract or sinus infection that required antibiotic therapy, with asthma who require chronic use of inhaled or systemic corticosteroid or with clinically significant sinusitis.
研究者
相似试验
进行中（未招募）
不适用
Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome. - Not applicableIrritable Bowel Syndrome.MedDRA version: 9.1Level: LLTClassification code 10023003Term: Irritable bowel syndromeEUCTR2008-000214-71-LVaboratorios Menarini S.A. (Menarini Group)620
进行中（未招募）
不适用
Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome. - Not applicableIrritable Bowel Syndrome.MedDRA version: 9.1Level: LLTClassification code 10023003Term: Irritable bowel syndromeEUCTR2008-000214-71-GBaboratorios Menarini S.A. (Menarini Group)620
进行中（未招募）
不适用
Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome. - Not applicableEUCTR2008-000214-71-DKaboratorios Menarini S.A. (Menarini Group)620
进行中（未招募）
不适用
Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome. - Not applicableIrritable Bowel Syndrome.MedDRA version: 9.1Level: LLTClassification code 10023003Term: Irritable bowel syndromeEUCTR2008-000214-71-SKaboratorios Menarini S.A. (Menarini Group)620
进行中（未招募）
不适用
Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome. - Not applicableIrritable Bowel Syndrome.MedDRA version: 9.1Level: LLTClassification code 10023003Term: Irritable bowel syndromeEUCTR2008-000214-71-DEaboratorios Menarini S.A. (Menarini Group)620